Connor Clark & Lunn Investment Management Ltd. Takes $1.21 Million Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 80,533 shares of the company's stock, valued at approximately $1,212,000. Connor Clark & Lunn Investment Management Ltd. owned 0.17% of Pacira BioSciences as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of PCRX. GAMMA Investing LLC raised its stake in shares of Pacira BioSciences by 229.6% during the 2nd quarter. GAMMA Investing LLC now owns 1,338 shares of the company's stock valued at $38,000 after buying an additional 932 shares during the last quarter. Park Place Capital Corp purchased a new position in Pacira BioSciences during the second quarter valued at approximately $46,000. Innealta Capital LLC acquired a new position in Pacira BioSciences in the second quarter valued at approximately $50,000. nVerses Capital LLC boosted its position in Pacira BioSciences by 800.0% in the 2nd quarter. nVerses Capital LLC now owns 1,800 shares of the company's stock worth $51,000 after purchasing an additional 1,600 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Pacira BioSciences during the 1st quarter worth approximately $106,000. Hedge funds and other institutional investors own 99.73% of the company's stock.

Pacira BioSciences Stock Down 3.7 %

Shares of Pacira BioSciences stock opened at $16.78 on Wednesday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The stock's 50 day simple moving average is $16.33 and its 200-day simple moving average is $20.05. Pacira BioSciences, Inc. has a 1-year low of $11.16 and a 1-year high of $35.95.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Barclays decreased their target price on shares of Pacira BioSciences from $25.00 to $17.00 and set an "equal weight" rating for the company in a research note on Tuesday, November 12th. Truist Financial cut Pacira BioSciences from a "buy" rating to a "sell" rating and dropped their target price for the company from $30.00 to $8.00 in a research report on Tuesday, August 13th. StockNews.com cut Pacira BioSciences from a "strong-buy" rating to a "buy" rating in a report on Monday, August 12th. Needham & Company LLC reiterated a "buy" rating and set a $22.00 price target on shares of Pacira BioSciences in a research report on Friday, November 8th. Finally, Piper Sandler cut Pacira BioSciences from an "overweight" rating to a "neutral" rating and cut their price objective for the company from $42.00 to $11.00 in a research report on Monday, August 12th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $23.50.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.